506 related articles for article (PubMed ID: 35114597)
1. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
[TBL] [Abstract][Full Text] [Related]
2. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.
Ruan Z; Liang M; Shang L; Lai M; Deng X; Su X
Pancreatology; 2021 Apr; 21(3):630-641. PubMed ID: 33707115
[TBL] [Abstract][Full Text] [Related]
3. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
Wang Y; Sun Q; Mu N; Sun X; Wang Y; Fan S; Su L; Liu X
Cell Commun Signal; 2020 Jul; 18(1):112. PubMed ID: 32665011
[TBL] [Abstract][Full Text] [Related]
4. PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of β-catenin and PD-L1.
Ma Y; Xia P; Wang Z; Xu J; Zhang L; Jiang Y
Neoplasia; 2021 Sep; 23(9):912-928. PubMed ID: 34325342
[TBL] [Abstract][Full Text] [Related]
5. Deubiquitination and Stabilization of PD-L1 by CSN5.
Lim SO; Li CW; Xia W; Cha JH; Chan LC; Wu Y; Chang SS; Lin WC; Hsu JM; Hsu YH; Kim T; Chang WC; Hsu JL; Yamaguchi H; Ding Q; Wang Y; Yang Y; Chen CH; Sahin AA; Yu D; Hortobagyi GN; Hung MC
Cancer Cell; 2016 Dec; 30(6):925-939. PubMed ID: 27866850
[TBL] [Abstract][Full Text] [Related]
6. CSN5 Promotes Hepatocellular Carcinoma Progression by SCARA5 Inhibition Through Suppressing β-Catenin Ubiquitination.
Liu H; Hu J; Pan H; Luo D; Huang M; Xu W
Dig Dis Sci; 2018 Jan; 63(1):155-165. PubMed ID: 29189991
[TBL] [Abstract][Full Text] [Related]
7. A Novel Link between Inflammation and Cancer.
Grinberg-Bleyer Y; Ghosh S
Cancer Cell; 2016 Dec; 30(6):829-830. PubMed ID: 27960080
[TBL] [Abstract][Full Text] [Related]
8. CSN5/JAB1 suppresses the WNT inhibitor DKK1 in colorectal cancer cells.
Jumpertz S; Hennes T; Asare Y; Schütz AK; Bernhagen J
Cell Signal; 2017 Jun; 34():38-46. PubMed ID: 28229932
[TBL] [Abstract][Full Text] [Related]
9. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.
Zou J; Xia H; Zhang C; Xu H; Tang Q; Zhu G; Li J; Bi F
Cancer Sci; 2021 Jul; 112(7):2664-2678. PubMed ID: 33934451
[TBL] [Abstract][Full Text] [Related]
10. CSN5 upregulates glycolysis to promote hepatocellular carcinoma metastasis via stabilizing the HK2 protein.
Huang M; Xiong H; Luo D; Xu B; Liu H
Exp Cell Res; 2020 Mar; 388(2):111876. PubMed ID: 31991125
[TBL] [Abstract][Full Text] [Related]
11. CSN5 controls the growth of osteosarcoma via modulating the EGFR/PI3K/Akt axis.
Wan Z; Huang S; Mo F; Yao Y; Liu G; Han Z; Chen M; Zhiyun L
Exp Cell Res; 2019 Nov; 384(2):111646. PubMed ID: 31560888
[TBL] [Abstract][Full Text] [Related]
12. Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis.
Sun L; Huang C; Zhu M; Guo S; Gao Q; Wang Q; Chen B; Li R; Zhao Y; Wang M; Chen Z; Shen B; Zhu W
Theranostics; 2020; 10(26):11950-11962. PubMed ID: 33204322
[No Abstract] [Full Text] [Related]
13. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
14. CSN5/Jab1 facilitates non-small cell lung cancer cell growth through stabilizing survivin.
Li J; Li Y; Wang B; Ma Y; Chen P
Biochem Biophys Res Commun; 2018 Jun; 500(2):132-138. PubMed ID: 29596838
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer.
Yamashita K; Iwatsuki M; Yasuda-Yoshihara N; Morinaga T; Nakao Y; Harada K; Eto K; Kurashige J; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Baba Y; Miyamoto Y; Yoshida N; Ajani JA; Baba H
Br J Cancer; 2021 Feb; 124(3):595-603. PubMed ID: 33100329
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer.
Yu W; Hua Y; Qiu H; Hao J; Zou K; Li Z; Hu S; Guo P; Chen M; Sui S; Xiong Y; Li F; Lu J; Guo W; Luo G; Deng W
Cell Death Dis; 2020 Jul; 11(7):506. PubMed ID: 32632098
[TBL] [Abstract][Full Text] [Related]
18. IKK-Mediated Regulation of the COP9 Signalosome via Phosphorylation of CSN5.
Zhang J; Zhao R; Yu C; Bryant CLN; Wu K; Liu Z; Ding Y; Zhao Y; Xue B; Pan ZQ; Li C; Huang L; Fang L
J Proteome Res; 2020 Mar; 19(3):1119-1130. PubMed ID: 31950832
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo.
Asare Y; Ommer M; Azombo FA; Alampour-Rajabi S; Sternkopf M; Sanati M; Gijbels MJ; Schmitz C; Sinitski D; Tilstam PV; Lue H; Gessner A; Lange D; Schmid JA; Weber C; Dichgans M; Jankowski J; Pardi R; de Winther MP; Noels H; Bernhagen J
Proc Natl Acad Sci U S A; 2017 Mar; 114(13):E2766-E2775. PubMed ID: 28292897
[TBL] [Abstract][Full Text] [Related]
20. Blockage of PD-L1 by FERMT3-mediated Wnt/β-catenin signalling regulates chemoresistance and immune evasion of colorectal cancer cells.
Tang Y; Nan N; Gui C; Zhou X; Jiang W; Zhou X
Clin Exp Pharmacol Physiol; 2022 Sep; 49(9):988-997. PubMed ID: 35672907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
